版本:
中国

BRIEF-Cerus provides update on Intercept red blood cell system

May 9 Cerus Corp

* Cerus announces exercise of additional BARDA contract options totaling $46.6 million to support intercept red blood cell system development

* Cerus corp- additional $46.6 million brings cerus' total allocation up to $88.4 million to date

* Cerus corp- recepi phase iii study protocol is under fda review, and redes phase iii study is open for enrollment

* Cerus corp- current allocations fund two of three expected phase iii studies for possible future pma submission Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐